Clinical Oncology
Volume 22, Issue 5 , Pages 325-333 , June 2010

Surgical Management of Non-small Cell Lung Cancer with Mediastinal Lymphadenopathy

  • G. Rocco

      Affiliations

    • Department of Thoracic Surgery and Oncology, National Cancer Institute, Pascale Foundation, Naples, Italy
    • Corresponding Author InformationAuthor for correspondence: G. Rocco, Department of Thoracic Surgery and Oncology, National Cancer Institute, Pascale Foundation – Via Semmola 81, 80131 Naples, Italy. Tel: +39-815903262; Fax: +39-815903823.
    • ,
  • F. Perrone

      Affiliations

    • Department of Thoracic Surgery and Oncology, National Cancer Institute, Pascale Foundation, Naples, Italy
    • ,
  • A. Rossi

      Affiliations

    • Division of Medical Oncology, “S.G. Moscati” Hospital, Avellino, Italy
    • ,
  • C. Gridelli

      Affiliations

    • Division of Medical Oncology, “S.G. Moscati” Hospital, Avellino, Italy

Received 28 January 2009 ,Accepted 22 January 2010.

References 

  1. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:706–714
  2. Robinson LA, Ruckdeschel JC, Wagner H, Stevens CW. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:243S–265S
  3. van Meerbeeck JP, Kramer GWPM, Van Schil PEY, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst. 2007;99:442–450
  4. Riquet M, Bagan P, Le Pimpec Barthes F, et al. Completely resected non-small cell lung cancer: reconsidering prognostic value and significance of N2 metastases. Ann Thorac Surg. 2007;84:1818–1824
  5. Cerfolio RJ, Maniscalco L, Bryant AS. The treatment of patients with stage IIIA non-small cell lung cancer from N2 disease: who returns to the surgical arena and who survives. Ann Thorac Surg. 2008;86:912–920
  6. Uy KL, Darling G, Xu W, et al. Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2007;134:188–193
  7. Van Schil P. Mortality associated with pneumonectomy after induction chemoradiation versus chemotherapy alone in stage IIIA-N2 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2008;135:718
  8. Pass HI. Lung cancer staging techniques and induction therapy: maybe timing is everything. J Clin Oncol. 2008;26:3306–3307
  9. Kuzdzal J, Zielinski M, Papla B, et al. The transcervical extended mediastinal lymphadenectomy versus cervical mediastinoscopy in non-small cell lung cancer staging. Eur J Cardiothorac Surg. 2007;31:88–94
  10. Zhong W, Yang X, Bai J, et al. Complete mediastinal lymphadenectomy: the core component of the multidisciplinary therapy in resectable non-small cell lung cancer. Eur J Cardiothorac Surg. 2008;34:187–195
  11. Scagliotti CV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543–3551
  12. Garrido P, Gonzalez-Larriba JL, Insa A, et al. Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901. J Clin Oncol 2007;25:4736–42.
  13. Rami Porta R, Wittekind C, Goldstraw P. International Association for the Study of Lung Cancer (IASLC) staging committee. Complete resection in lung cancer surgery: proposed definition. Lung Cancer. 2005;49:25–33
  14. Sakao Y, Miyamoto H, Yamazaki A, et al. Prognostic significance of metastasis to the highest mediastinal lymph node in nonsmall cell lung cancer. Ann Thorac Surg. 2006;81:292–297
  15. Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol. 2000;18;2981–2989
  16. Takeda S, Maeda H, Okada T, et al. Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA-IIIB) lung cancer. Eur J Cardiothorac Surg. 2006;30:184–189
  17. Lardinois D, De Leyn P, Van Schil P, et al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardiothorac Surg. 2006;30:787–792
  18. Ernst A, Anantham D, Eberhardt R, Krasnik M, Herth FJ. Diagnosis of mediastinal adenopathy-real-time endobronchial ultrasound guided needle aspiration versus mediastinoscopy. J Thorac Oncol. 2008;3:577–582
  19. Cerfolio RJ, Bryant AS. Survival of patients with unsuspected N2 (stage IIIA) nonsmall-cell lung cancer. Ann Thorac Surg. 2008;86:362–367
  20. Ferguson MK. Optimal management when unsuspected N2 nodal disease is identified during thoracotomy for lung cancer: cost-effectiveness analysis. J Thorac Cardiovasc Surg. 2003;126:1935–1942
  21. Keller SM, Vangel MG, Wagner H, et al. Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease. J Thorac Cardiovasc Surg. 2004;128:130–137
  22. Inoue M, Sawabata N, Takeda S, Ohta M, Ohno Y, Maeda H. Results of surgical intervention for p-stage IIIA (N2) non-small cell lung cancer: acceptable prognosis predicted by complete resection in patients with single N2 disease with primary tumor in the upper lobe. J Thorac Cardiovasc Surg. 2004;127:1100–1106
  23. Riquet M, Assouad J, Bagan P, et al. Skip mediastinal lymph node metastasis and lung cancer: a particular N2 subgroup with a better prognosis. Ann Thorac Surg. 2005;79:225–233
  24. Ohta Y, Shimizu Y, Minato H, et al. Results of initial operations in non–small cell lung cancer patients with single-level N2 disease. Ann Thorac Surg. 2006;81:427–433
  25. Asamura H, Nakayama H, Kondo H, Tsuchiya R, Naruke T. Lobe-specific extent of systematic lymph node dissection for non-small cell lung carcinomas according to a retrospective study of metastasis and prognosis. J Thorac Cardiovasc Surg. 1999;117:1102–1111
  26. Tsubota N, Yoshimura M. Skip metastasis and hidden N2 disease in lung cancer: how successful is mediastinal dissection?. Surg Today. 1996;26:169–172
  27. Martini N, Flehinger BJ, Zaman MB, Beattie EJ. Results of resection in non-oat cell carcinoma of the lung with mediastinal lymph node metastases. Ann Surg. 1983;198:386–397
  28. Ishida T, Yano T, Maeda K, Kaneko S, Tateishi M, Sugimachi K. Strategy for lymphadenectomy in lung cancer three centimetres or less in diameter. Ann Thorac Surg. 1990;50:708–713
  29. Puma F. Isolated mediastinal skip metastasis in lung cancer: is it real N2 disease?. J Thorac Cardiovasc Surg. 2005;129:235
  30. Yokomise H, Nakashima T, Masuya D, et al. Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2007;133:1179–1185
  31. Witte B, Hürtgen M. Video-assisted mediastinoscopic lymphadenectomy (VAMLA). J Thorac Oncol. 2007;2:367–369
  32. Port JL, Korst RJ, Levin MA, et al. Surgical resection for residual N2 disease after induction chemotherapy. Ann Thorac Surg. 2005;79:1686–1690
  33. Betticher DC, Hsu Schmitz SF, Totsch M, et al. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer. 2006;94:1099–1106
  34. Mansour Z, Kochetkova EA, Santelmo N, et al. Persistent N2 disease after induction therapy does not jeopardize early and medium term outcomes of pneumonectomy. Ann Thorac Surg. 2008;86:228–233
  35. Van Schil P, Van Meerbeeck J, Kramer G, et al. Morbidity and mortality in the surgery arm of EORTC 08941 trial. Eur Respir J. 2005;26:192–197
  36. Doddoli C, Barlesi F, Trousse D, et al. One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: an uncertain balance between risks and benefits. J Thorac Cardiovasc Surg. 2005;130:416–425
  37. Albain KS, Swann RS, Rusch V, et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA (pN2) non-small-cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309). J Clin Oncol. 2005;23:624s;[abstract 7014] Full report in Lancet 2009;374:379–386.
  38. Martin J, Ginsberg RJ, Abolhoda A, et al. Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg. 2001;72:1149–1154
  39. Gudbjartsson T, Gyllstedt E, Pikwer A, Jönsson P. Early surgical results after pneumonectomy for non-small cell lung cancer are not affected by preoperative radiotherapy and chemotherapy. Ann Thorac Surg. 2008;86:376–382
  40. Daly BDT, Fernando HC, Ketcedjian A, et al. Pneumonectomy after radiation and concurrent chemotherapy for nonsmall cell lung cancer. Ann Thorac Surg. 2006;82:227–231
  41. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552–3559
  42. Pisters KMW, Evans WK, Azzoli CG, et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I–IIIA resectable non-small cell lung cancer guideline. J Clin Oncol. 2007;25:5505–5518
  43. Douillard JY, Rosell R, De Lena M, et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the Adjuvant Navelbine International Trialist Association (ANITA) randomized trial. Int J Radiat Oncol Biol Phys. 2008;72:695–701
  44. Le Pechoux C, Dunant A, Pignon JP, et al. Need for a new trial to evaluate adjuvant postoperative radiotherapy in non-small-cell lung cancer patients with N2 mediastinal involvement. J Clin Oncol. 2007;25:e10–e11
  45. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994;86:673–680
  46. Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer. 1998;21:1–6
  47. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994;330:153–158
  48. Rosell R, Gomez-Codina J, Camps C, et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer. 1999;26:7–14
  49. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol. 2002;20:247–253
  50. Beghmans T, Paesmans M, Meert AP, et al. Survival improvement in resectable non-small-cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer. 2005;49:13–23
  51. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2007;355:983–991
  52. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol. 2007;25:2742–2754
  53. Azzoli CG, Park BJ, Pao W, et al. Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer. A time for excitement and equipoise. J Thor Oncol. 2008;3:84–93
  54. Peterson P, Park K, Fossella F, et al. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma?. J Thor Oncol. 2007;2(Suppl. 4):S581;[abstract P2–328]
  55. Ciuleanu TE, Brodowicz T, Belani CP, et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: a phase III study. J Clin Oncol. 2008;26(15S):426s;[abstract 8011]
  56. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer. 2006;107:1589–1596
  57. Sandler A, Gray R, Perry MC, et al. Paclitaxel–carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med. 2006;355:2542–2550
  58. Manegold C, von Pawel J, Zatloukal P, et al. BO17704 (AVAIL): a phase III randomised study of first-line bevacizumab combined with cisplatin/gemcitabine (CG) in patients (PTS) with advanced or recurrent non-squamous, non-small cell lung cancer (NSCLC). Ann Oncol. 2008;19(Suppl. 8):viii1;[abstract LBA1]
  59. Rizvi NA, Rusch V, Zhao B. Single agent bevacizumab and bevacizumab in combination with docetaxel and cisplatin as induction therapy for resectable IB-IIIA non-small cell lung cancer. J Clin Oncol. 2007;25(18S):687s;[abstract 18045]
  60. Available from: http://www.cancer.gov [accessed 4.01.08].
  61. Johnson DH, Rusch VW, Turrisi AT. Scalpels, beams, drugs, and dreams: challenges of stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst. 2007;99:418

PII: S0936-6555(10)00044-0

doi: 10.1016/j.clon.2010.01.007

Clinical Oncology
Volume 22, Issue 5 , Pages 325-333 , June 2010

Article Tools